Literature DB >> 12950601

Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy.

Masahiko Nakamura1, Robin C Spiller, David A Barrett, Judata I D Wibawa, Naoki Kumagai, Kanji Tsuchimoto, Takeshi Tanaka.   

Abstract

BACKGROUND: Amoxicillin and clarithromycin are key antibiotics in proton pump inhibitor-based Helicobacter pylori eradication therapies. AIMS: To study gastric mucus and tissue concentrations and collect basic data about optimal antibacterial doses.
METHODS: Plasma, gastric mucosa and gastric juice antibiotic concentrations were measured following either low- or high-dose amoxicillin (750 or 1000 mg b.i.d.) and clarithromycin (400 or 500 mg b.i.d.) given in combination with omeprazole 20 mg bid to 12 male volunteers in an open crossover design. Gastric juice and mucosal biopsy collection was performed either 2 (n=6) or 6 hours (n=6) after dosing.
RESULTS: Amoxicillin concentrations 2 hours after high dosage were gastric juice > gastric body > antral mucosa > plasma. At 6 hours, plasma and gastric juice concentrations were still above the MIC for amoxicillin-susceptible bacteria but no antibiotic was detectable in mucosa samples. Clarithromycin concentrations after high dosage were gastric juice > mucosa > serum; all above the MIC for clarithromycin-susceptible bacteria at both 2 and 6 hours.
CONCLUSIONS: Both dosage regimens provided effective antibiotic concentrations in gastric juice at 2 hours. After dosing, both antibiotics demonstrated high gastric tissue concentrations via local diffusion while clarithromycin also provided sustained delivery (6 hours) via gastric mucosa penetration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950601     DOI: 10.1046/j.1523-5378.2003.00156.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  12 in total

1.  Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection.

Authors:  Ala I Sharara; Fayez S Sarkis; Mustapha M El-Halabi; Ahmad Malli; Nabil M Mansour; Cecilio Azar; Mohamad A Eloubeidi; Fadi H Mourad; Kassem Barada; Ismail Sukkarieh
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

2.  Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication.

Authors:  Kai Y Liu; Fang C Du; Qiang Fu; Wei J Zhang; Hong W Sun; Yi Zhang; Le L Gan; Zhi Y Yue; Quan M Zou; Gang Guo
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 3.  Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.

Authors:  Abhijit A Date; Justin Hanes; Laura M Ensign
Journal:  J Control Release       Date:  2016-06-09       Impact factor: 9.776

4.  Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole.

Authors:  Hai-lun Zheng; Yong-mei Hu; Jun-jun Bao; Jian-ming Xu
Journal:  Acta Pharmacol Sin       Date:  2010-03-22       Impact factor: 6.150

5.  Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study.

Authors:  Kazuhide Higuchi; Takama Maekawa; Koichiro Nakagawa; Shinji Chouno; Takanobu Hayakumo; Naomi Tomono; Akio Orino; Hirohisa Tanimura; Kan Asahina; Naotaka Matsuura; Motohiko Endo; Masanori Hirano; Choitsu Sakamoto; Tsutomu Inomoto; Tetsuo Arakawa
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 6.  Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.

Authors:  Francis Mégraud
Journal:  Gut Microbes       Date:  2013-08-05

7.  Efficacy of a Low-Dose Omeprazole-Based Triple-Therapy Regimen for Helicobacter pylori Eradication Independent of Cytochrome P450 Genotype : The Japanese MACH Study.

Authors:  Hajime Kuwayama; Gordon Luk; Shunichi Yoshida; Takefumi Nakamura; Mitsuhiko Kubo; Naomi Uemura; Shigeru Harasawa; Mitsuru Kaise; Eiko Sanuki; Ken Haruma; Masaki Inoue; Tomohiko Shimatani; Hiroshi Mieno; Masahiro Kawanishi; Hidenobu Watanabe; Mituyoshi Nakashima; Saburo Nakazawa
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 8.  Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Authors:  Evariste Tshibangu-Kabamba; Yoshio Yamaoka
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-17       Impact factor: 46.802

Review 9.  Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori: A Literature Review.

Authors:  Ilaria Maria Saracino; Matteo Pavoni; Angelo Zullo; Giulia Fiorini; Tiziana Lazzarotto; Claudio Borghi; Dino Vaira
Journal:  Antibiotics (Basel)       Date:  2021-04-14

10.  Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations.

Authors:  Hideo Yonezawa; Takako Osaki; Tomoko Hanawa; Satoshi Kurata; Kuniyasu Ochiai; Shigeru Kamiya
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.